Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07356154 · ClinicalTrials.gov registry record · Phase 1

A Study of Revumenib and Mezigdomide in People With Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
52
Enrollment target
10
Study locations

NCT07356154 is a Phase 1 study of Acute Myeloid Leukemia and Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 52 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (55% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07356154, a Phase 1 study of Acute Myeloid Leukemia and Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
52 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

Conditions Studied

Acute Myeloid Leukemia Leukemia Acute Lymphoblastic Leukemia Acute Leukemia Mixed Phenotype Acute Leukemia Refractory Acute Leukemia Refractory Leukemia Relapse Leukemia

Interventions

  • DRUG Revumenib
  • DRUG Mezigdomide

Study Locations (10)

New York

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

California

  • City of Hope Cancer Center (Data collection only) - Duarte

North Carolina

  • University of North Carolina (Data Collection Only) - Chapel Hill

Texas

  • MD Anderson Cancer Center (Data Collection Only) - Houston

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2026-01-16
Est. Completion 2029-01-16
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07356154

The ClinicalTrials.gov registry entry for NCT07356154 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (55% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Revumenib is the first listed.

NCT07356154 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, California.

Frequently Asked Questions

What is clinical trial NCT07356154 about?

NCT07356154 is a clinical study titled "A Study of Revumenib and Mezigdomide in People With Leukemia". The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

What is the current status of trial NCT07356154?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2026-01-16. Estimated completion is 2029-01-16.

What conditions does trial NCT07356154 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Mixed Phenotype Acute Leukemia.

What interventions are being tested in trial NCT07356154?

The interventions under investigation include: Revumenib (DRUG), Mezigdomide (DRUG).

Who is sponsoring clinical trial NCT07356154?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07356154 being conducted?

This trial has 10 study locations across California, New Jersey, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.